CFA Pharma
ActiveCFA Pharma has been active since 1986 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €154k and a net result of €7k. Equity is growing by ~2.8% per year across the filed fiscal years. Its solvency ranks better than 46% of 17987 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.4% (very low).
Checked score
Score 2025
76
/ 100
Excellent▼ -18 vs 2024
The score combines four axes. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability22▼-65
Solvency68▼-15
Growth52▼-26
Stability100
Bankruptcy probability, 12 months
0.4%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €12k at 30 days acceptable
Liquidity ample (current ratio 2.64 against 3.33 in 2024), but 70.7% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
29.3%
Return on assets
1.3%
Age of the figures
8 mo
neutral · Filed after the deadline
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 31-08-2026, 31 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 10 filingsDeviation from the deadline
2025
31 d late
2024
236 d late
2023
31 d late
2022
13 d early
2021
27 d early
2020
24 d early
2019
30 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
13-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, micro schema
Equity
€154k▲ 0.5%
2024 · €153k
2018: €119k
2019: €139k
2020: €144k
2021: €129k
2022: €140k
2023: €137k
2024: €153k
2018 → 2025
Total assets
€525k▲ 34.8%
2024 · €390k
2018: €303k
2019: €311k
2020: €300k
2021: €260k
2022: €247k
2023: €472k
2024: €390k
2018 → 2025
Net result
€7k▼ 74.7%
2024 · €27k
2018: €9k
2019: €20k
2020: €24k
2021: €25k
2022: €27k
2023: €645
2024: €27k
2018 → 2025
Working capital
€172k▼ 5.4%
2024 · €182k
2018: €60k
2019: €77k
2020: €77k
2021: €55k
2022: €57k
2023: €164k
2024: €182k
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€129k-€140k▲ 7.8%€137k▼ 2.2%€153k▲ 12.2%€154k▲ 0.5%
Operating result€37k-€37k=€1k▼ 97.1%€34k▲ 2,986%€22k▼ 35.7%
Net result€25k-€27k▲ 10.5%€645▼ 97.6%€27k▲ 4,032%€7k▼ 74.7%
Turnover and EBIT margin not published: the abbreviated or micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result falls in 2025; 2025 is 36% below 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €525k
Fixed assets
€249k▲ 90.9%
Current assets
€277k▲ 6.6%
Equity and liabilities €525k
Equity
€154k▲ 0.5%
Debt
€371k▲ 57.0%
The debt ratio rises from 60.7% to 70.7%: debt grows faster than equity.
Key figures and ratios
EBITDA
€49k▼
2024 · €52k
Cash flow
€34k▼
2024 · €45k
Solvency
29.3%▼
2024 · 39.3%
Current ratio
2.64▼
2024 · 3.33
Quick ratio
2.64▼
2024 · 3.33
Debt / equity
2.41▲
2024 · 1.54
ROE
4.4%▼
2024 · 17.4%
ROA
1.3%▼
2024 · 6.8%
Interest coverage
4.78▼
2024 · 7.40
Debt
€371k▲
2024 · €237k
Debt ≤ 1 year
€105k▲
2024 · €78k
Debt > 1 year
€266k▲
2024 · €159k
Income taxes
€5k▲
2024 · €208
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€390k€525k▲
Fixed assets21/28€130k€249k▲
Tangible fixed assets22/27€130k€249k▲
Land and buildings22-€136k
Other tangible fixed assets26€130k€112k▼
Current assets29/58€259k€277k▲
Amounts receivable within one year40/41€252k€270k▲
Trade receivables40€172k€39k▼
Other amounts receivable41€80k€231k▲
Cash at bank and in hand54/58€8k€6k▼
Equity and liabilities
Total equity and liabilities10/49€390k€525k▲
Equity10/15€153k€154k▲
Contributions10/11€28k€28k=
Reserves13€97k€98k▲
Non-distributable reserves130/1€3k€3k=
Reserves not available under the articles1311€3k€3k=
Distributable reserves133€94k€95k▲
Profit (loss) carried forward14€28k€28k=
Amounts payable17/49€237k€371k▲
Amounts payable after more than one year17€159k€266k▲
Financial debts170/4€149k€256k▲
Trade debts175€10k€10k=
Amounts payable within one year42/48€78k€105k▲
Current portion of amounts payable after more than one year42€30k€39k▲
Trade debts44€38k€46k▲
Suppliers440/4€38k€46k▲
Taxes, remuneration and social security45-€5k
Taxes450/3-€5k
Other amounts payable47/48€10k€16k▲
Income statement
Code20242025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€18k€28k▲
Other operating charges640/8€1k€3k▲
Gross operating margin9900€53k€52k▼
Operating profit (loss)9901€34k€22k▼
Financial income75/76B€246€0▼
Recurring financial income75€246€0▼
Financial charges65/66B€7k€10k▲
Recurring financial charges65€7k€10k▲
Profit (loss) for the period before taxes9903€27k€11k▼
Income taxes67/77€208€5k▲
Profit (loss) for the period9904€27k€7k▼
Profit (loss) for the period to be appropriated9905€27k€7k▼
Appropriation of the result
Profit (loss) to be appropriated9906€55k€35k▼
Profit (loss) brought forward from the previous period14P€28k€28k=
Transfer from equity791/2€0-
Transfer to equity691/2€17k€743▼
To other reserves6921€17k€743▼
Profit to be distributed694/7€10k€6k▼
Return on contributions (dividend)694€0-
Directors or managers695€10k€6k▼
The notes to these accounts (12 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
31-08
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema · 31 days late
24-03
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema · 236 days late
2024
31-12
Financial
Equity above €150kEq €153k ▲12.2%
7 profitable years in a row build equity to €153k.
31-08
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema · 31 days late
2023
31-12
Financial
Weakest financial yearnet €645 ▼97.6%
Net result drops to €645, the lowest in the series; recovery starts the following year.
18-07
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
2022
31-12
Financial
Highest result since 2018net €27k ▲10.5%
Operating result €37k, net result €27k, both a record.
04-07
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
2021
07-07
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
2020
01-07
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
2019
04-07
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema
2018
12-07
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema
2017
26-06
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
6 directors, no change since 2024
BONTE Anne-Sophie
CurrentDirector · since 08-01-2024
MILDRO
CurrentDirector · since 08-01-2024 · Public limited company · perm. rep.: VERBEKE Alexandre
01-02-2024
Sampers Cécile: Resigned as Director
01-02-2024
Sampers Gilbert: Resigned as Director
01-02-2024
Sampers Hubert: Resigned as Director
01-02-2024
Sampers Roza: Resigned as Director
08-01-2024
BONTE Anne-Sophie: Appointed as Director
08-01-2024
MILDRO: Appointed as Director
Location & real-estate footprint
Registered office, Ieper · 1 establishment unit since 1986
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Blauwepoortstraat 18902 IeperGround area
569 m²
Building footprint
139 m²
Volume, LiDAR
896 m³
Parcel 33036C0366/00R004, Flanders · tallest building 10.4 m, ±2 floors. Linked by address, not a title deed.
1 establishment unit
Blauwepoortstraat 1, 8902 Ieper
since 19862.035.214.804
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 33036C0366/00R004 | Flanders | 568 m² | 1 · 139 m² | 10.4 m · 2 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
APOTHEEK WINTERS MAASEIK
BE 0475.857.947
Maaseik · Eq €154k
Pharmacie Vallée Bailly
BE 0894.357.024
Braine-l'Alleud · Eq €154k
PHARMACIE HERZET - PRATTE
BE 0715.957.790
Beloeil · Eq €154k
SIVAHE
BE 0772.612.126
Hasselt · Eq €154k
APOTHEEK DE STERRE
BE 0458.740.219
Gent · Eq €154k
Of 5,208 companies in sector 47730 we hold annual accounts for 3,850. 3,553 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded24-03-1986
Fiscal year end31-12
Activities, NACEBEL
47730Retail sale of pharmaceutical products
52310
Sources
Crossroads Bank for EnterprisesNational Bank · 40 filingsAddress and cadastre registers
Data from official sources, last processed on 13-09-2026. Scores and ratios are computed by Checked and are not a credit decision.